Nano Dimension (NNDM) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 Jun, 2026Executive summary
Murchinson Ltd. and affiliates, holding 7.7% of shares, are soliciting proxies to enact significant governance changes at an extraordinary general meeting, citing underperformance and poor governance.
The meeting agenda includes proposals to declassify the board, require shareholder approval for poison pills and major transactions, remove three directors, and appoint three new nominees.
Murchinson recommends voting for all its proposals, aiming to align the board with shareholder interests and enhance accountability.
Voting matters and shareholder proposals
Proposals include a non-binding advisory vote on the company's strategic alternatives review, declassification of the board, restrictions on poison pills, shareholder approval for major transactions, removal of three directors, and appointment of three new directors.
Each proposal has specific approval thresholds, with most requiring a simple majority, except the board declassification, which requires a 70% majority.
Shareholders can vote by proxy, with detailed procedures for ADS and ordinary share holders.
Board of directors and corporate governance
Proposal to amend Article 39 to declassify the board and require annual director elections.
Proposal to remove directors Robert Pons, Joshua Rosensweig, and David Stehlin, and any new directors appointed after May 21, 2026.
Proposal to appoint Moshe Rozenbaum, Eliezer Eli Tarlow, and Paul Fruchthandler as new directors, who are presented as independent and highly qualified.
Latest events from Nano Dimension
- Revenue up 46% to $58.7M, Q2 margin 45.9%, net loss widens, cost cuts to reduce cash burn.NNDM
Q2 2026 - Shareholders face a pivotal vote on Board control, with future input on strategic transactions.NNDM
Proxy filing - Proxy contest seeks board overhaul, annual elections, and more shareholder control over key decisions.NNDM
Proxy filing - Shareholders will vote on strategic direction, governance amendments, and board composition changes.NNDM
Proxy filing - Board supports strategic review and declassification, opposes governance and director changes.NNDM
Proxy filing - Proposed merger with Infinite Epigenetics offers a 20% premium and pivots to AI-powered diagnostics.NNDM
Proxy filing - $890M merger forms a Nasdaq-listed AI diagnostics leader targeting the $90–94B U.S. market.NNDM
M&A announcement - Q3 revenue surged 81% to $26.9M, but margins fell; Q4 guidance: $31.5M–$33.5M.NNDM
Q3 2025 - Record Q2 revenue, improved margins, and a transformative acquisition highlight best quarter.NNDM
Q2 2024